December 18, 2013 | Israeli stem cell company Pluristem Therapeutics is moving forward with the agreement reached with Korean company CHA Bio & Diostech signed last June. The two companies have agreed on a strategic partnership which will also include a $10.4 million mutual investment via share swap.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments